Gawo 2A Chithandizo cha Khansa Yam'mapapo 2026: Zatsopano za ELCC pa Neo-Adjuvant Therapy 

Gawo 2A chithandizo cha khansa ya m'mapapo mu 2026 zasintha kwambiri, kuchoka ku njira zopangira opaleshoni yokha kupita ku njira zambiri zophatikizira chithandizo cha neo-adjuvant. Malangizo apano akugogomezera kuphatikiza immunotherapy ndi chemotherapy musanachite opaleshoni kuti apititse patsogolo kuchuluka kwa ma pathological reaction (pCR) komanso kupulumuka kwanthawi yayitali. Zambiri zaposachedwa kuchokera ku European Lung Cancer Congress (ELCC) ya 2026 ikuwonetsa kuti ma regimens atsopano, kuphatikiza ma inhibitors apawiri-checkpoint ndi ma immunogenic radiotherapy, akutanthauziranso zotsatira za khansa ya m'mapapo yomwe siing'ono yaing'ono (NSCLC).

Kumvetsetsa Gawo 2A Khansa Yam'mapapo Yosakhala Yang'ono Yang'ono

Gawo 2A NSCLC likuyimira nthawi yovuta pakuwongolera khansa ya m'mapapo pomwe chotupacho chimakhala chokhazikika koma chimakhala ndi chiopsezo cha matenda a micrometastatic. M'mbiri, kuchotsedwa kwa opaleshoni nthawi yomweyo kunali muyezo wa chisamaliro. Komabe, oncology yamakono imazindikira kuti chithandizo chamankhwala chomwe chimaperekedwa asanachite opaleshoni amatha kuthetsa matenda osawoneka omwe amafalikira msanga.

Tanthauzo la Gawo 2A nthawi zambiri limakhudza zotupa zazikulu kuposa 3 cm koma zosapitilira 4 cm popanda kukhudzidwa ndi ma lymph node, kapena zotupa zazing'ono zomwe zimawukiridwa kwinakwake. Kukhazikika kolondola ndikofunikira, chifukwa kumapereka mwayi kwa ma protocol a neo-adjuvant.

• Kukula kwa Chotupa: Nthawi zambiri pakati pa 3 cm ndi 4 cm pagulu la T2a N0 M0.
• Mkhalidwe wa Lymph Node: Nthawi zambiri palibe metastasis ya m'dera la lymph node (N0), ngakhale kukhudzidwa kwapang'onopang'ono ndikodetsa nkhawa.
• Resectability: Odwala amaonedwa kuti ndi oyenera kuchotsedwa kwathunthu opaleshoni (R0 resection).

Cholinga cha chithandizo sikungochotsa chotupa koma kuwonetsetsa kuti munthu akhale ndi moyo wautali popanda matenda (DFS) ndi kupulumuka konse (OS). Kusintha kwa pre-operative systemic therapy kumafuna kutsitsa chotupacho, kupangitsa opaleshoni kukhala yosavuta komanso yogwira mtima.

Kusintha kuchokera ku Adjuvant kupita ku Neo-Adjuvant Therapy

Kwa zaka zambiri, adjuvant chemotherapy (omwe amaperekedwa pambuyo pa opaleshoni) anali chizolowezi. Ngakhale zinali zopindulitsa pang'ono, kutsata nthawi zambiri kunali koyipa chifukwa cha zovuta zochira pambuyo pa opaleshoni. Neo-adjuvant therapy, yoperekedwa opaleshoni isanakwane, imayankhulirana ndi izi pochiza wodwalayo akadali wokwanira.

Mayesero aposachedwa azachipatala awonetsa kuti njira za neo-adjuvant zimapereka mitengo yayikulu ya pCR poyerekeza ndi makonzedwe a adjuvant. Kukwaniritsa pCR, pomwe palibe ma cell a khansa omwe amakhalabe m'chitsanzo cha opaleshoni, kumagwirizana kwambiri ndi zotsatira zabwino za nthawi yayitali. Kusintha kwa paradigm uku ndikofunika kwambiri pazachipatala cha 2026.

Kuphatikiza apo, chithandizo cha neo-adjuvant chimalola asing'anga kuti awone momwe chotupa chimayankhira munthawi yeniyeni. Ngati chotupa sichikuyankha ku regimen yoyamba, chithandizo chikhoza kusinthidwa musanachite opaleshoni, kupewa njira zopanda pake pazochitika zaukali za matenda.

2026 ELCC Zopambana mu Neo-Adjuvant Strategies

European Lung Cancer Congress ya 2026 (ELCC) idakhala ngati nsanja yofunikira pakuwulula zosintha mu NSCLC yokhazikika. Maphunziro angapo omwe adaperekedwa ku Copenhagen adayika zizindikiro zatsopano za zomwe zimapanga chisamaliro chokhazikika cha Gawo 2A ndi matenda otsogola kwanuko.

Chimodzi mwazokambirana chofunikira kwambiri chinali chokhudzana ndi malire a msana wa "PD-1 inhibitor kuphatikiza chemotherapy". Ngakhale maphunziro monga CheckMate 816 ndi KEYNOTE-671 adakhazikitsa kuphatikiza uku, odwala ambiri amalepherabe kukwaniritsa pCR. Kafukufuku watsopano akuyang'ana pa kukulitsa ma regimens awa mosamala.

Akatswiri ku ELCC 2026 adawonetsa kuti tsogolo liri pazophatikizira zamunthu. Izi zikuphatikizanso kuwonjezera zida zatsopano monga ma antibodies a bispecific kapena kuphatikiza mankhwala omwe amapezeka komweko monga radiotherapy kuti alimbikitse chitetezo chamthupi chisanakhudze khungu.

Phunziro la Neo-RISE Lung: Paradigm Yatsopano

Chiwonetsero chodziwika bwino ku ELCC 2026 chinali chidziwitso choyambirira kuchokera ku kafukufuku wa Neo-RISE Lung. Kuyesa kwatsopano kumeneku kudasanthula njira ya katatu: immunogenic radiotherapy yotsatiridwa ndi PD-1/VEGF bispecific antibody (ivonescimab) ndi chemotherapy.

Zolinga za mapangidwe awa ndi synergistic. Radiotherapy imayambitsa kufa kwa maselo, kutulutsa ma antigen otupa. Bispecific antibody kenako imatsekereza malo awiri oteteza chitetezo nthawi imodzi ndikuletsa angiogenesis kudzera kuponderezedwa kwa VEGF. "Nkhonya imodzi ndi ziwiri" izi zimalimbitsa chitetezo chamthupi kuposa mankhwala amphamvu okha.

• Mlingo wa Mayankho a Objective (ORR): Kafukufukuyu adanenanso za ORR yochititsa chidwi ya 100% mu gulu loyesedwa.
• Pathological Complete Response (pCR): Mitengo idafika 55.1%, yokwera kwambiri kuposa zowongolera zakale za ~ 24%.
• Mayankho Akuluakulu a Pathological (MPR): Kukwaniritsidwa mu 79.3% ya odwala.
• Kutsitsa: 88.2% ya odwala adakumana ndi chotupa chotsitsa, zomwe zidapangitsa kuti opaleshoni ichotsedwe mosavuta.

Chofunika kwambiri, odwala onse omwe adachita opaleshoni adapeza R0 resection, kutanthauza kuti palibe maselo a khansa omwe adasiyidwa m'mphepete. Deta iyi ikuwonetsa kuti kwa odwala a Stage 2A, kuwonjezera ma radiotherapy ndi ma biologics omwe amatsata pawiri akhoza kukhala mulingo watsopano wazinthu zomwe zili pachiwopsezo chachikulu.

KEYNOTE-671 Deta Yanthawi Yaitali: Mphamvu ya Perioperative Immunotherapy

Mwala wina wapangodya wa 2026 ELCC unali kusanthula kwanthawi yayitali kwa mayeso a KEYNOTE-671. Kafukufuku wa Phase 3 adawunika pembrolizumab kuphatikiza ndi chemotherapy ngati chithandizo cha neo-adjuvant, kutsatiridwa ndi adjuvant pembrolizumab monotherapy.

Zomwe zapezedwa posachedwa, kutengera miyezi yopitilira 60 yotsatiridwa, zidatsimikizira kuti phindu la perioperative immunotherapy ndi lolimba. Chofunikira ndichakuti, zomwe adazilembazo zidasokoneza odwala ndi momwe amayankhira ma pathological, kupereka chidziwitso chambiri kwa asing'anga omwe akuchiza matenda a Stage 2A.

Ngakhale odwala omwe sanapeze yankho lathunthu la pathological (non-pCR) adapeza phindu lalikulu la kupulumuka popanda zochitika (EFS). Chiŵerengero cha ngozi cha EFS mu gulu lopanda pCR chinali 0.69, kusonyeza kuchepetsa 31% pa chiopsezo chobwereza kapena imfa poyerekeza ndi placebo.

Kwa iwo omwe adakwanitsa pCR, zotsatira zake zinali zapadera, ndi chiwerengero cha EFS cha zaka 5 cha 81%. Izi zimalimbitsa lingaliro lakuti ngakhale pCR ndi cholembera champhamvu, machitidwe a immunotherapy amateteza odwala mosasamala kanthu za kuya kwa kuyankhidwa.

Njira Zochiritsira Zothandizira Oyendetsa-Mutated Stage 2A Khansa Yam'mapapo

Sikuti makhansa onse a m'mapapo a Gawo 2A amayendetsedwa ndi njira zomwezo. Pafupifupi 15-20% ya odwala akumadzulo komanso 50% ya odwala aku Asia amakhala ndi masinthidwe oyendetsa ngati EGFR kapena ALK. Kwa anthu awa, immunotherapy yokha sikungakhale njira yabwino kwambiri ya neo-adjuvant.

ELCC ya 2026 idapereka zosintha zovuta pazamankhwala omwe akuwunikiridwa pamachitidwe ochitapo kanthu. Mlandu wa ADAURA udakhazikitsa kale osimertinib ngati muyezo wamankhwala adjuvant mu EGFR-mutated NSCLC. Deta yatsopano tsopano ikukankhira othandizira awa mu danga la neo-adjuvant.

EGFR Mutations ndi TOP Study Insights

Ngakhale kuti kafukufuku wa TOP adayang'ana kwambiri matenda apamwamba a metastatic, zotsatira zake pa chithandizo chamankhwala oyambilira ndizozama. Kafukufukuyu adafufuza osimertinib kuphatikiza ndi chemotherapy motsutsana ndi osimertinib okha mwa odwala omwe ali ndi kusintha kwa EGFR komanso kusintha kwa TP53.

Zosintha za TP53 zimadziwika kuti zimapereka kukana kwa EGFR tyrosine kinase inhibitors (TKIs). Kafukufuku wa TOP adawonetsa kuti kuwonjezera chemotherapy ku osimertinib kuwirikiza kawiri kupulumuka kwaulere (PFS) m'gulu lachiwopsezo chachikulu ichi. Izi zikuwonetsa kuti kwa odwala a Stage 2A omwe ali ndi kusintha kwa EGFR/TP53, njira yophatikizira ingakhale yofunikira ngakhale pakuchiritsa.

Madokotala tsopano akukangana ngati angatengere kuphatikiza kwa chemo-immunotherapy kapena chemo-TKI pamankhwala a neo-adjuvant pamagulu oyendetsa bwino. Mgwirizanowu ukupita ku zisankho zotsogozedwa ndi mamolekyulu m'malo mongotengera njira imodzi yokha ya immunotherapy.

ALK Positive Disease: The ALINA Study Impact

Kwa odwala omwe ali ndi ALK rearrangements, kafukufuku wa ALINA wakhala akusintha masewera. Zinawonetsa kuti adjuvant alectinib imathandizira kwambiri DFS poyerekeza ndi chemotherapy-based chemotherapy. Ngakhale deta ya neo-adjuvant ndi yocheperapo kusiyana ndi deta ya adjuvant, mphamvu ya alectinib mu zotupa zocheperachepera isanayambike ikufufuzidwa mwachangu.

Mu 2026, chidwi chili pakupeza nthawi yoyenera ya chithandizo chomwe mukufuna. Kodi iyenera kuperekedwa kokha pambuyo pa opaleshoni, kapena kodi njira ya "sandwich" (neo-adjuvant + adjuvant) iyenera kutengedwa? Zizindikiro zoyamba zikuwonetsa kuti chithandizo chamankhwala chomwe chisanachitike chingathandize kuti maopaleshoni asamayende bwino, kuteteza mapapu kwa odwala a Stage 2A.

Kuwunika Kuyerekeza kwa Njira Zochizira

Kusankha choyenera Gawo 2a chithandizo cha khansa ya m'mapapo zimafunika kupenda ubwino ndi kuopsa kwa njira zosiyanasiyana. Gome lotsatirali likufanizira njira zomwe zidakambidwa pa ELCC 2026.

Kuyerekezera kumeneku kukugogomezera kuti “kukula kumodzi sikukwanira zonse.” Kukhalapo kwa zizindikiro zenizeni za majini kapena kuchuluka kwa chotupacho kungatsimikizire ngati wodwala amapindula kwambiri ndi mankhwala a chemo-immunotherapy, njira yoyesera yowonjezereka, kapena othandizira omwe akufuna.

Ubwino ndi kuipa kwa Neo-Adjuvant Approaches

Kulandila chithandizo cha neo-adjuvant cha khansa ya m'mapapo ya Stage 2A kumapereka maubwino apadera komanso kumabweretsa zovuta zomwe magulu azigawo zosiyanasiyana amayenera kuthana nazo.

• Ubwino:
  • Kuwongolera Koyambirira Kwadongosolo: Amachiza ma micrometastases nthawi yomweyo, kuchepetsa chiopsezo cha kubwereza kwakutali.
  • Mu Vivo Sensitivity Testing: Amalola madokotala kuti awone ngati chotupacho chikucheperachepera, kupereka chidziwitso chamtsogolo.
  • Kupititsa patsogolo Resectability: Itha kutsitsa zotupa, kutembenuza milandu yokhazikika m'malire kuti ichotse ma R0 resections.
  • Kutsatira Kwapamwamba: Odwala amalekerera chithandizo chamankhwala bwino asanachite opaleshoni kusiyana ndi kuchira.
• Zoyipa:
  • Kuchedwerapo Opaleshoni: Kuchiza kumatenga milungu ingapo, zomwe zingayambitse nkhawa kapena kuchulukirachulukira muzochitika zosawerengeka.
  • Kuvuta Kwa Opaleshoni: Kutupa kapena fibrosis chifukwa cha chithandizo nthawi zina kumapangitsa kuti dissection ikhale yovuta kwambiri kwa madokotala ochita opaleshoni.
  • Zowopsa za Toxicity: Zochitika zoyipa zokhudzana ndi chitetezo chamthupi (irAEs) zitha kuchitika musanachite opaleshoni, zomwe zitha kupangitsa kuti pakhale vuto la anesthesia kapena kuchiritsa mabala.

Ngakhale zovutazi, umboni wochuluka wochokera ku 2026 umathandizira phindu la njira za neo-adjuvant kwa odwala oyenerera a Stage 2A. Chinsinsi chagona pakusankha odwala mosamala komanso kulumikizana mwamphamvu m'magulu osiyanasiyana.

Upangiri wapapang'onopang'ono ku Utsogoleri Wamakono wa Gawo 2A

Kuyenda paulendo wochizira khansa ya m'mapapo ya Stage 2A mu 2026 kumaphatikizapo njira yokhazikika, yosiyana siyana. Nayi mayendedwe anthawi zonse kutengera machitidwe abwino apano.

• Khwerero 1: Kusanthula Kwathunthu ndi Mbiri Yamaselo
  
  Pamaso pa chisankho chilichonse chamankhwala, odwala amawunika ma PET-CT ndi MRI yaubongo kuti aletse metastasis yakutali. Chofunika kwambiri, biopsy ya minofu iyenera kuyesedwa pa EGFR, ALK, ROS1, ndi PD-L1 mawu. Gawo ili limatsimikizira ngati wodwalayo alowa mu immunotherapy kapena njira yochizira.
• Khwerero 2: Kuunikanso kwa Magulu Osiyanasiyana (MDT).
  
  Gulu lopangidwa ndi maopaleshoni am'mimba, akatswiri azachipatala, akatswiri a radiation oncologists, ndi akatswiri azachipatala akuwunikanso za nkhaniyi. Amawunika kuyambiranso ndikukambirana zaubwino womwe ungakhalepo wa neo-adjuvant therapy motsutsana ndi opaleshoni yam'tsogolo potengera deta yaposachedwa ya ELCC.
• Khwerero 3: Kuyambitsa Neo-Adjuvant Therapy
  
  Ngati ndi kotheka, wodwalayo amayambitsa regimen yosankhidwa. Kwa odwala omwe alibe dalaivala, izi nthawi zambiri zimakhala zozungulira 3-4 za platinamu-doublet chemotherapy kuphatikiza PD-1/PD-L1 inhibitor. Paziwopsezo zazikulu, mayeso azachipatala ophatikiza ma antibodies a bispecific kapena radiotherapy atha kuperekedwa.
• Khwerero 4: Kubwezeretsanso ndi Kukonzekera Opaleshoni
  
  Mukamaliza kuzungulira kwa neo-adjuvant, kujambula kubwereza kumachitika kuti muwunikire kuyankha. Ngati matendawa ali okhazikika kapena akuyankha, opaleshoni imakonzedwa kawirikawiri masabata a 3-6 pambuyo pa mlingo wotsiriza wa immunotherapy kuti athetse chitetezo cha mthupi.
• Khwerero 5: Kuchotsa Opaleshoni ndi Kuwunika kwa Pathological
  
  Dokotala wa opaleshoni amapanga lobectomy kapena segmentectomy ndi lymph node dissection. Katswiriyu amawunika chitsanzocho kuti adziwe Major Pathological Response (MPR) kapena Pathological Complete Response (pCR), yomwe imatsogolera chithandizo china.
• Gawo 6: Kuphatikiza kwa Adjuvant
  
  Malingana ndi ndondomeko yoyamba ndi zotsatira za pathological, odwala akhoza kupitiriza ndi adjuvant immunotherapy (mwachitsanzo, pembrolizumab) kwa chaka chimodzi kapena kusinthana ndi mankhwala omwe akugwiritsidwa ntchito (mwachitsanzo, osimertinib) ngati kusintha kwapezeka. Njira ya "perioperative" iyi imatsimikizira chitetezo chopitilira kubwereza.

Udindo wa Minimal Residual Disease Monitoring (MRD).

Chida chomwe chikubwera mu 2026 ndikugwiritsa ntchito chotupa chozungulira DNA (ctDNA) kuyang'anira Matenda Ochepa Otsalira (MRD). Ukadaulowu umazindikira tinthu ting'onoting'ono ta DNA ya khansa m'magazi zomwe kujambula sikungathe kuwona.

Kafukufuku woperekedwa pamisonkhano yaposachedwa akuwonetsa kuti kuchotsa ctDNA panthawi yamankhwala a neo-adjuvant ndiko kulosera kwamphamvu kwa kupulumuka kwa nthawi yayitali. Mosiyana ndi zimenezi, ctDNA yosalekeza pambuyo pa opaleshoni imatha kuzindikira odwala omwe amafunikira chithandizo chowonjezera cha adjuvant. Ngakhale sikunafunikire konsekonse, kuwunika kwa MRD kukukhala gawo lodziwika bwino la khansa ya m'mapapo ya Gawo 2A.

Mwachitsanzo, kafukufuku wa cadonilimab (a PD-1/CTLA-4 bispecific antibody) adawonetsa kuti odwala omwe adapeza chilolezo cha ctDNA anali ndi moyo wautali wopanda kupitilira. Maselo a ma molekyulu awa amalola kusintha kwamankhwala kwamphamvu, kuchoka ku ma protocol a nthawi yokhazikika.

Malingaliro a Zachipatala kwa Anthu Apadera

Kuchiza khansa ya m'mapapo ya Gawo 2A sikufanana pakati pa anthu onse. Anthu enieni amafunikira njira zofananira kuti azitha kuchita bwino ndi chitetezo.

Odwala Okalamba ndi Omwe Ali ndi Vuto Losagwira Ntchito

Akuluakulu okalamba kapena odwala omwe ali ndi vuto la comorbidities nthawi zambiri amavutika ndi kawopsedwe wa mlingo wathunthu wa chemo-immunotherapy. Mayesero a ETOP ADEPPT ndi maphunziro ofanana adafufuza njira zochepetsera zochepetsera kapena mankhwala omwe amayang'aniridwa ndi wothandizira mmodzi m'maguluwa.

Mu 2026, zomwe zikuchitika ndi "kuchepa" kwa odwala ofooka. Izi zitha kuphatikiza kugwiritsa ntchito immunotherapy monotherapy ngati mawu a PD-L1 ali okwera, kapena kusankha othandizira ngati pali kusintha kwa dalaivala, kupewa zotsatira zoyipa za platinamu chemotherapy. Cholingacho chimakhalabe chochiritsidwa, koma njirayo imasinthidwa kuti wodwalayo athe kumaliza chithandizo.

Odwala omwe ali ndi Brain Metastases

Ngakhale Gawo 2A silikutanthauza kufalikira kwakutali, ma metastases amatsenga amatsenga nthawi zina amapezeka pakuwunika mwatsatanetsatane. Ma TKI a m'badwo watsopano monga osimertinib ndi alectinib ali ndi malowedwe abwino kwambiri apakati a mitsempha (CNS).

Kwa odwala omwe ali ndi ma metastases ochepa muubongo omwe amapezedwa panthawi yagawo, chithandizo chamankhwala ndi CNS-active mankhwala nthawi zambiri chimayikidwa patsogolo musanayambe chithandizo chaubongo. Maphunziro a ARTS ndi ALINA alimbitsa chidaliro pochiza matenda oyambilira ndi othandizira omwe amateteza ubongo, kuchepetsa kufunikira kwa radiation ya cranial nthawi zina.

Malangizo Amtsogolo ndi Kafukufuku Wopitilira

Malo a Gawo 2a chithandizo cha khansa ya m'mapapo ndi zamphamvu. Pamene tikudutsa mu 2026, madera angapo a kafukufuku akulonjeza kuti adzawonjezera zotsatira. Kuphatikizika kwa luntha lochita kupanga mu ma radiomics kumathandizira kulosera odwala omwe angayankhe pamankhwala a neo-adjuvant chithandizo chisanayambe.

Kuphatikiza apo, kupanga ma conjugates a m'badwo wotsatira wa antibody-drug conjugates (ADCs) kukutsegula zitseko zatsopano. Mayesero okhudzana ndi ma ADC otsogozedwa ndi HER3 ndi othandizira omwe akutsata TROP2 akuwonetsa lonjezano mu dongosolo la neo-adjuvant, lomwe lingathe kupereka zosankha kwa odwala omwe samayankha ku immunotherapy wamba.

Lingaliro la "total neoadjuvant therapy" likukulanso. Njirayi imathetsa chithandizo cha adjuvant kwathunthu, kupereka chithandizo chonse chamankhwala musanachite opaleshoni. Deta yoyambirira ikuwonetsa kuti izi zitha kufewetsa ulendo wa odwala ndikuwongolera kutsatira, ngakhale zomwe zakhala zikuyenda kwanthawi yayitali zikadali kukula.

Kufunika kwa Mayesero Achipatala

Chifukwa cha kusinthika kwachangu kwa miyezo yamankhwala, kulembetsa m'mayesero azachipatala kumalimbikitsidwa kwambiri kwa odwala a Stage 2A. Mayesero ngati Galaxy-L-01, kufufuza garsorasib kuphatikizidwa ndi anlotinib ya masinthidwe a KRAS G12C, amapereka mwayi wopeza zithandizo zotsogola zisanachitike.

Kutenga nawo mbali m'maphunzirowa sikumangopindulitsa wodwala payekhapayekha komanso kumathandizira kuti chidziwitso chapadziko lonse chizidziwitso, ndikufulumizitsa kupeza machiritso. Madokotala akulimbikitsidwa kuti akambirane za kuyenerera kwa mayesero ndi wodwala aliyense woyenerera pa matenda.

Kutsiliza: Nyengo Yatsopano Yachiyembekezo ya Gawo 2A Khansa Yam'mapapo

Chaka cha 2026 chikuwonetsa kusintha kotsimikizika pakuwongolera khansa ya m'mapapo ya Stage 2A. Apita masiku pamene opaleshoni inali yankho lokhalo. Lero, Gawo 2a chithandizo cha khansa ya m'mapapo ndizovuta, zoyeserera zambiri zophatikiza kulondola kwamankhwala omwe akuwunikiridwa, mphamvu ya immunotherapy, ndi nthawi yoyenera ya njira zothandizira neo-adjuvant.

Zambiri kuchokera ku 2026 ELCC, makamaka zokhudzana ndi kafukufuku wa Neo-RISE Lung ndi zotsatira za KEYNOTE-671 za nthawi yayitali, zimatsimikizira kuti titha kupeza machiritso apamwamba kuposa kale lonse. Mwakusintha chithandizo chamunthu potengera mbiri ya mamolekyu komanso kuphatikiza kwapang'onopang'ono monga ma antibodies a bispecific ndi immunogenic radiotherapy, asing'anga akusintha milandu yomwe inali yovuta kukhala nkhani zopambana.

Kwa odwala ndi mabanja, izi zikutanthauza tsogolo lokhala ndi zosankha zambiri, kukhala ndi moyo wabwinoko, komanso moyo wabwino. Pamene kafukufuku akupitilira kuwulula zovuta za biology ya khansa ya m'mapapo, njira zake zimalozera njira zogwira mtima kwambiri, zopanda poizoni, komanso njira zosamalira anthu. Mgwirizano pakati pa madokotala ochita opaleshoni, oncologists, ndi ofufuza akadali mwala wapangodya wa kupita patsogolo kumeneku, kuonetsetsa kuti wodwala aliyense wa Stage 2A amalandira mwayi wabwino kwambiri wochiritsira.